{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:09:20Z","timestamp":1789661360594,"version":"4.0.1"},"reference-count":74,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004742","name":"National Academy of Sciences of Ukraine (NASU)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004742","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Russian Scientific Foundation","award":["14-14-00882"],"award-info":[{"award-number":["14-14-00882"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gene"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.gene.2015.12.064","type":"journal-article","created":{"date-parts":[[2015,12,31]],"date-time":"2015-12-31T12:31:26Z","timestamp":1451565086000},"page":"58-68","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["mTOR inhibitor temsirolimus and MEK1\/2 inhibitor U0126 promote chromosomal instability and cell type-dependent phenotype changes of glioblastoma cells"],"prefix":"10.1016","volume":"579","author":[{"given":"A.A.","family":"Stepanenko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.V.","family":"Andreieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.V.","family":"Korets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.O.","family":"Mykytenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.P.","family":"Baklaushev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.P.","family":"Chekhonin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.V.","family":"Dmitrenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gene.2015.12.064_bb0005","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.molcel.2011.01.001","article-title":"FKBP12 binds to acylated H-ras and promotes depalmitoylation","volume":"41","author":"Ahearn","year":"2011","journal-title":"Mol. Cell"},{"key":"10.1016\/j.gene.2015.12.064_bb0010","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1042\/BST20110609","article-title":"Cross-talk between mitogenic Ras\/MAPK and survival PI3K\/Akt pathways: a fine balance","volume":"40","author":"Aksamitiene","year":"2012","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.gene.2015.12.064_bb0015","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/nbt.2017","article-title":"Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity","volume":"29","author":"Anastassiadis","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.gene.2015.12.064_bb0020","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/hmg\/ddi444","article-title":"Hamartin, the tuberous sclerosis complex 1 gene product, interacts with polo-like kinase 1 in a phosphorylation-dependent manner","volume":"15","author":"Astrinidis","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.gene.2015.12.064_bb0025","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/gcc.20739","article-title":"The transcription factor SP1 regulates centriole function and chromosomal stability through a functional interaction with the mammalian target of rapamycin\/raptor complex.","volume":"49","author":"Astrinidis","year":"2010","journal-title":"Genes Chromosom. Cancer"},{"key":"10.1016\/j.gene.2015.12.064_bb0030","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1042\/BJ20070797","article-title":"The selectivity of protein kinase inhibitors: a further update","volume":"408","author":"Bain","year":"2007","journal-title":"Biochem. J."},{"key":"10.1016\/j.gene.2015.12.064_bb0035","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s004120050335","article-title":"Inhibition of the Mr 70,000S6 kinase pathway by rapamycin results in chromosome malsegregation in yeast and mammalian cells","volume":"107","author":"Bonatti","year":"1998","journal-title":"Chromosoma"},{"key":"10.1016\/j.gene.2015.12.064_bb0040","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/em.20145","article-title":"Altered centrosomes in ataxia-telangiectasia cells and rapamycin-treated Chinese hamster cells","volume":"46","author":"Bonatti","year":"2005","journal-title":"Environ. Mol. Mutagen."},{"key":"10.1016\/j.gene.2015.12.064_bb0045","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1093\/annonc\/mdt155","article-title":"Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors","volume":"24","author":"Choueiri","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.gene.2015.12.064_bb0050","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/1940-6207.CAPR-14-0313-T","article-title":"Prevention of carcinogen and inflammation-induced dermal cancer by oral rapamycin includes reducing genetic damage","volume":"8","author":"Dao","year":"2015","journal-title":"Cancer Prev. Res. (Phila)"},{"key":"10.1016\/j.gene.2015.12.064_bb0055","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1158\/0008-5472.CAN-13-2381","article-title":"ERKs in cancer: friends or foes?","volume":"74","author":"Desch\u00eanes-Simard","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.gene.2015.12.064_bb0060","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.febslet.2004.11.084","article-title":"PD98059 and U0126 activate AMP-activated protein kinase by increasing the cellular AMP:ATP ratio and not via inhibition of the MAP kinase pathway","volume":"579","author":"Dokladda","year":"2005","journal-title":"FEBS Lett."},{"key":"10.1016\/j.gene.2015.12.064_bb0065","first-page":"293","article-title":"The chromosomal basis of cancer","volume":"27","author":"Duesberg","year":"2005","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.gene.2015.12.064_bb0070","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.drup.2007.02.003","article-title":"Cancer drug resistance: the central role of the karyotype","volume":"10","author":"Duesberg","year":"2007","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.gene.2015.12.064_bb0075","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.4161\/cc.10.13.16352","article-title":"Is carcinogenesis a form of speciation?","volume":"10","author":"Duesberg","year":"2011","journal-title":"Cell Cycle"},{"key":"10.1016\/j.gene.2015.12.064_bb0080","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1007\/s00018-014-1677-1","article-title":"Longevity, aging and rapamycin","volume":"71","author":"Ehninger","year":"2014","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.gene.2015.12.064_bb0085","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2174\/1389203715666140331113753","article-title":"Molecular chaperone activity and biological regulatory actions of the TPR-domain immunophilins FKBP51 and FKBP52","volume":"15","author":"Erlejman","year":"2014","journal-title":"Curr. Protein Pept. Sci."},{"key":"10.1016\/j.gene.2015.12.064_bb0090","doi-asserted-by":"crossref","first-page":"18623","DOI":"10.1074\/jbc.273.29.18623","article-title":"Identification of a novel inhibitor of mitogen-activated protein kinase kinase","volume":"273","author":"Favata","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.gene.2015.12.064_bb0095","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.tox.2014.09.003","article-title":"The National Library of Medicine's (NLM) Hazardous Substances Data Bank (HSDB): background, recent enhancements and future plans","volume":"325","author":"Fonger","year":"2014","journal-title":"Toxicology"},{"key":"10.1016\/j.gene.2015.12.064_bb0100","doi-asserted-by":"crossref","first-page":"966","DOI":"10.4161\/cbt.12.11.18136","article-title":"A metabolic perturbation by U0126 identifies a role for glutamine in resveratrol-induced cell death","volume":"12","author":"Freeman","year":"2011","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.gene.2015.12.064_bb0105","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.bbrc.2014.06.105","article-title":"Rapamycin-binding FKBP25 associates with diverse proteins that form large intracellular entities","volume":"450","author":"Galat","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.gene.2015.12.064_bb0110","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ijbiomac.2014.05.060","article-title":"Diversified targets of FKBP25 and its complex with rapamycin","volume":"69","author":"Galat","year":"2014","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.gene.2015.12.064_bb0115","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2144\/000113083","article-title":"TScratch: a novel and simple software tool for automated analysis of monolayer wound healing assays","volume":"46","author":"Geb\u00e4ck","year":"2009","journal-title":"Biotechniques"},{"key":"10.1016\/j.gene.2015.12.064_bb0120","doi-asserted-by":"crossref","first-page":"e54072","DOI":"10.1371\/journal.pone.0054072","article-title":"OpenCFU, a new free and open-source software to count cell colonies and other circular objects","volume":"8","author":"Geissmann","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.gene.2015.12.064_bb0125","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.267pe24","article-title":"The pharmacology of mTOR inhibition.","volume":"2","author":"Guertin","year":"2009","journal-title":"Sci. Signal."},{"key":"10.1016\/j.gene.2015.12.064_bb0130","article-title":"Mtor-Fanconi anemia DNA damage repair pathway in cancer","volume":"2","author":"Guo","year":"2014","journal-title":"J. Oncobiomarkers"},{"key":"10.1016\/j.gene.2015.12.064_bb0135","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.mce.2014.07.015","article-title":"Influence of mTOR in energy and metabolic homeostasis","volume":"397","author":"Haissaguerre","year":"2014","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.gene.2015.12.064_bb0140","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1038\/bjc.2013.602","article-title":"Acquired resistance to temsirolimus in human renal cell carcinoma cells is mediated by the constitutive activation of signal transduction pathways through mTORC2","volume":"109","author":"Harada","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.gene.2015.12.064_bb0145","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.4161\/cc.25508","article-title":"FKBPs and the Akt\/mTOR pathway","volume":"12","author":"Hausch","year":"2013","journal-title":"Cell Cycle"},{"key":"10.1016\/j.gene.2015.12.064_bb0150","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/bies.200800182","article-title":"The genome-centric concept: resynthesis of evolutionary theory","volume":"31","author":"Heng","year":"2009","journal-title":"BioEssays"},{"key":"10.1016\/j.gene.2015.12.064_bb0155","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/jcp.21799","article-title":"Genetic and epigenetic heterogeneity in cancer: a genome-centric perspective","volume":"220","author":"Heng","year":"2009","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.gene.2015.12.064_bb0160","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/jcb.22497","article-title":"The evolutionary mechanism of cancer","volume":"109","author":"Heng","year":"2010","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.gene.2015.12.064_bb0165","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10555-013-9427-7","article-title":"Chromosomal instability (CIN): what it is and why it is crucial to cancer evolution","volume":"32","author":"Heng","year":"2013","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.gene.2015.12.064_bb0170","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/jcp.24233","article-title":"Why imatinib remains an exception of cancer research","volume":"228","author":"Horne","year":"2013","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.gene.2015.12.064_bb0175","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.semcdb.2014.08.004","article-title":"mTORC1 signaling controls multiple steps in ribosome biogenesis","volume":"36","author":"Iadevaia","year":"2014","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.gene.2015.12.064_bb0180","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.canlet.2012.05.003","article-title":"Acetylation of histone H3 prevents resistance development caused by chronic mTOR inhibition in renal cell carcinoma cells","volume":"324","author":"Juengel","year":"2012","journal-title":"Cancer Lett."},{"key":"10.1016\/j.gene.2015.12.064_bb0185","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.neo.2014.03.011","article-title":"Resistance to the mTOR inhibitor temsirolimus alters adhesion and migration behavior of renal cell carcinoma cells through an integrin \u03b15- and integrin \u03b23-dependent mechanism","volume":"16","author":"Juengel","year":"2014","journal-title":"Neoplasia"},{"key":"10.1016\/j.gene.2015.12.064_bb0190","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1476-4598-13-152","article-title":"HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A","volume":"13","author":"Juengel","year":"2014","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.gene.2015.12.064_bb0195","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1158\/0008-5472.CAN-10-3604","article-title":"Chromosomal instability confers intrinsic multidrug resistance","volume":"71","author":"Lee","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.gene.2015.12.064_bb0200","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/toxsci\/kfp238","article-title":"Rapamycin inhibits yeast nucleotide excision repair independently of tor kinases","volume":"113","author":"Limson","year":"2010","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.gene.2015.12.064_bb0205","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1517\/13543776.2013.828695","article-title":"FK506-binding protein 12 ligands: a patent review","volume":"23","author":"Liu","year":"2013","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.gene.2015.12.064_bb0210","doi-asserted-by":"crossref","first-page":"528","DOI":"10.4161\/cc.27378","article-title":"Genome chaos: survival strategy during crisis","volume":"13","author":"Liu","year":"2014","journal-title":"Cell Cycle"},{"key":"10.1016\/j.gene.2015.12.064_bb0215","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/nbm.2848","article-title":"Treatment with the MEK inhibitor U0126 induces decreased hyperpolarized pyruvate to lactate conversion in breast, but not prostate, cancer cells","volume":"26","author":"Lodi","year":"2013","journal-title":"NMR Biomed."},{"key":"10.1016\/j.gene.2015.12.064_bb0220","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/nbm.3109","article-title":"MR-detectable metabolic consequences of mitogen-activated protein kinase kinase (MEK) inhibition","volume":"27","author":"Lodi","year":"2014","journal-title":"NMR Biomed."},{"key":"10.1016\/j.gene.2015.12.064_bb0225","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.4161\/cc.29082","article-title":"The other side of the coin: the tumor-suppressive aspect of oncogenes and the oncogenic aspect of tumor-suppressive genes, such as those along the CCND-CDK4\/6-RB axis","volume":"13","author":"Lou","year":"2014","journal-title":"Cell Cycle"},{"key":"10.1016\/j.gene.2015.12.064_bb0230","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.18632\/oncotarget.3006","article-title":"Rapamycin inhibits mSin1 phosphorylation independently of mTORC1 and mTORC2","volume":"6","author":"Luo","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.gene.2015.12.064_bb0235","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.bbamcr.2006.10.001","article-title":"Roles of the Raf\/MEK\/ERK pathway in cell growth, malignant transformation and drug resistance","volume":"1773","author":"McCubrey","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.gene.2015.12.064_bb0240","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.tibs.2011.03.006","article-title":"The Ras\u2013ERK and PI3K-mTOR pathways: cross-talk and compensation","volume":"36","author":"Mendoza","year":"2011","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.gene.2015.12.064_bb0245","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1021\/cn500288n","article-title":"U0126 protects cells against oxidative stress independent of its function as a MEK inhibitor","volume":"6","author":"Ong","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.gene.2015.12.064_bb0250","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/neuonc\/nou164","article-title":"The mTOR signaling pathway as a treatment target for intracranial neoplasms","volume":"17","author":"Pachow","year":"2015","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.gene.2015.12.064_bb0255","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/2159-8290.CD-14-0293","article-title":"Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype","volume":"5","author":"Paraiso","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.gene.2015.12.064_bb0260","series-title":"F1000Prime Rep. 6","first-page":"52.","article-title":"mTOR and lysosome regulation.","author":"Puertollano","year":"2014"},{"key":"10.1016\/j.gene.2015.12.064_bb0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0065166","article-title":"Incidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysis","volume":"8","author":"Qi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.gene.2015.12.064_bb0270","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1074\/jbc.M112.430082","article-title":"Acute mitochondrial inhibition by mitogen-activated protein kinase\/extracellular signal-regulated kinase kinase (MEK) 1\/2 inhibitors regulates proliferation","volume":"288","author":"Ripple","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.gene.2015.12.064_bb0275","doi-asserted-by":"crossref","first-page":"ra30","DOI":"10.1126\/scisignal.2004815","article-title":"BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling.","volume":"7","author":"Sanchez-Laorden","year":"2014","journal-title":"Sci. Signal."},{"key":"10.1016\/j.gene.2015.12.064_bb0280","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/acel.12313","article-title":"Rapamycin-mediated mTORC2 inhibition is determined by the relative expression of FK506-binding proteins","volume":"14","author":"Schreiber","year":"2015","journal-title":"Aging Cell"},{"key":"10.1016\/j.gene.2015.12.064_bb0285","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nrm3757","article-title":"Making new contacts: the mTOR network in metabolism and signalling crosstalk","volume":"15","author":"Shimobayashi","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.gene.2015.12.064_bb0290","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ctrv.2013.04.005","article-title":"Metabolic complications with the use of mTOR inhibitors for cancer therapy","volume":"40","author":"Sivendran","year":"2014","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.gene.2015.12.064_bb0295","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.4161\/cc.7.8.5737","article-title":"RB status governs differential sensitivity to cytotoxic and molecularly-targeted therapeutic agents","volume":"7","author":"Stengel","year":"2008","journal-title":"Cell Cycle"},{"key":"10.1016\/j.gene.2015.12.064_bb0300","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.gene.2015.05.065","article-title":"HEK293 in cell biology and cancer research: phenotype, karyotype, tumorigenicity, and stress-induced genome-phenotype evolution","volume":"569","author":"Stepanenko","year":"2015","journal-title":"Gene"},{"key":"10.1016\/j.gene.2015.12.064_bb0305","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.gene.2015.08.009","article-title":"Pitfalls of the MTT assay: direct and off-target effects of inhibitors can result in over\/underestimation of cell viability","volume":"574","author":"Stepanenko","year":"2015","journal-title":"Gene"},{"key":"10.1016\/j.gene.2015.12.064_bb0310","doi-asserted-by":"crossref","first-page":"267","DOI":"10.7124\/bc.000059","article-title":"Evolutionary karyotypic theory of cancer versus conventional cancer gene mutation theory","volume":"28","author":"Stepanenko","year":"2012","journal-title":"Biopolym. Cell"},{"key":"10.1016\/j.gene.2015.12.064_bb0315","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3103\/S0095452712020041","article-title":"Immortalization and malignant transformation of Eukaryotic cells","volume":"46","author":"Stepanenko","year":"2012","journal-title":"Cytol. Genet."},{"key":"10.1016\/j.gene.2015.12.064_bb0320","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.gene.2014.02.053","article-title":"Karyotypically distinct U251, U373, and SNB19 glioma cell lines are of the same origin but have different drug treatment sensitivities","volume":"540","author":"Stepanenko","year":"2014","journal-title":"Gene"},{"key":"10.1016\/j.gene.2015.12.064_bb0325","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.gene.2013.07.047","article-title":"Antagonistic functional duality of cancer genes","volume":"529","author":"Stepanenko","year":"2013","journal-title":"Gene"},{"key":"10.1016\/j.gene.2015.12.064_bb0330","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.mrfmmm.2014.12.006","article-title":"Step-wise and punctuated genome evolution drive phenotype changes of tumor cells","volume":"771","author":"Stepanenko","year":"2015","journal-title":"Mutat. Res. Mol. Mech. Mutagen."},{"key":"10.1016\/j.gene.2015.12.064_bb0340","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2011.60","article-title":"Diverse system stresses: common mechanisms of chromosome fragmentation","volume":"2","author":"Stevens","year":"2011","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.gene.2015.12.064_bb0345","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.canlet.2011.08.026","article-title":"The cdk1-cyclin B complex is involved in everolimus triggered resistance in the PC3 prostate cancer cell line","volume":"313","author":"Tsaur","year":"2011","journal-title":"Cancer Lett."},{"key":"10.1016\/j.gene.2015.12.064_bb0350","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/bjc.2012.313","article-title":"Resistance to the mTOR-inhibitor RAD001 elevates integrin \u03b12- and \u03b21-triggered motility, migration and invasion of prostate cancer cells","volume":"107","author":"Tsaur","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.gene.2015.12.064_bb0355","doi-asserted-by":"crossref","first-page":"995","DOI":"10.15252\/emmm.201403959","article-title":"TORC2-a new player in genome stability.","volume":"6","author":"Weisman","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.gene.2015.12.064_bb0360","first-page":"255","article-title":"Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance","volume":"11","author":"Wu","year":"2014","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.gene.2015.12.064_bb0365","first-page":"263","article-title":"mTOR signaling from cellular senescence to organismal aging.","volume":"5","author":"Xu","year":"2014","journal-title":"Aging Dis."},{"key":"10.1016\/j.gene.2015.12.064_bb0370","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.critrevonc.2013.01.007","article-title":"The treatment of glioblastomas: a systematic update on clinical Phase III trials","volume":"87","author":"Yin","year":"2013","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.gene.2015.12.064_bb0375","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrm3025","article-title":"mTOR: from growth signal integration to cancer, diabetes and ageing","volume":"12","author":"Zoncu","year":"2011","journal-title":"Nat. Rev. Mol. Cell Biol."}],"container-title":["Gene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111915015760?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111915015760?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T10:46:03Z","timestamp":1718275563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378111915015760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S0378111915015760"],"URL":"https:\/\/doi.org\/10.1016\/j.gene.2015.12.064","relation":{},"ISSN":["0378-1119"],"issn-type":[{"value":"0378-1119","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"mTOR inhibitor temsirolimus and MEK1\/2 inhibitor U0126 promote chromosomal instability and cell type-dependent phenotype changes of glioblastoma cells","name":"articletitle","label":"Article Title"},{"value":"Gene","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gene.2015.12.064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}